Director/PDMR Shareholding
1 May 2019 12:00 BST
Transactions by Persons Discharging Managerial Responsibilities
Disclosure under Article 19 of the EU Market Abuse Regulation
AstraZeneca PLC (the Company) announces that, on 29 and 30 April 2019, it was notified of transactions in the Company's ordinary shares of $0.25 each (Ordinary Shares) and American Depositary Shares (ADSs) by certain Persons Discharging Managerial Responsibilities of the Company (PDMRs) as set out below. Two ADSs are equivalent to one Ordinary Share.
| PDMR | Position | Nature of the transaction | Quantity | Price |
| Pascal Soriot | Chief Executive Officer | Purchase of Ordinary Shares | 17,100 | GB£58.255 |
| Philip Broadley | Non-Executive Director | Purchase of Ordinary Shares | 520 | GB£57.38 |
| Sheri McCoy | Non-Executive Director | Purchase of ADSs | 2,372 | US$38.1783 |
| Sheri McCoy | Non-Executive Director | Purchase of ADSs | 100 | US$38.172 |
| Deborah DiSanzo | Non-Executive Director | Purchase of ADSs | 1,000 | US$38.3056 |
Further details are set out in the attached notifications, made in accordance with the requirements of the EU Market Abuse Regulation.
| 1 | Details of the person discharging managerial responsibilities / person closely associated | |||||
| a) | Name | Pascal Soriot | ||||
| 2 | Reason for the notification | |||||
| a) | Position/status | Chief Executive Officer | ||||
| b) | Initial notification /Amendment | Initial notification | ||||
| 3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||
| a) | Name | AstraZeneca PLC | ||||
| b) | LEI | PY6ZZQWO2IZFZC3IOL08 | ||||
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||
| a) | Description of the financial instrument, type of instrument Identification code | Ordinary Shares of US$0.25 each in AstraZeneca PLC GB0009895292 | ||||
| b) | Nature of the transaction | Share purchase | ||||
| c) | Price(s) and volume(s) | Price(s) | Volume(s) | GB£58.255 | 17,100 | |
| d) | Aggregated information - Aggregated volume - Price | Not applicable - single transaction | ||||
| e) | Date of the transaction | 29 April 2019 | ||||
| f) | Place of the transaction | XLON | ||||
| 1 | Details of the person discharging managerial responsibilities / person closely associated | |||||
| a) | Name | Philip Broadley | ||||
| 2 | Reason for the notification | |||||
| a) | Position/status | Non-Executive Director | ||||
| b) | Initial notification /Amendment | Initial notification | ||||
| 3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||
| a) | Name | AstraZeneca PLC | ||||
| b) | LEI | PY6ZZQWO2IZFZC3IOL08 | ||||
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||
| a) | Description of the financial instrument, type of instrument Identification code | Ordinary Shares of US$0.25 each in AstraZeneca PLC GB0009895292 | ||||
| b) | Nature of the transaction | Share purchase | ||||
| c) | Price(s) and volume(s) | Price(s) | Volume(s) | GB£57.38 | 520 | |
| d) | Aggregated information - Aggregated volume - Price | Not applicable - single transaction | ||||
| e) | Date of the transaction | 30 April 2019 | ||||
| f) | Place of the transaction | XLON | ||||
| 1 | Details of the person discharging managerial responsibilities / person closely associated | |||||||
| a) | Name | Sheri McCoy | ||||||
| 2 | Reason for the notification | |||||||
| a) | Position/status | Non-Executive Director | ||||||
| b) | Initial notification /Amendment | Initial notification | ||||||
| 3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||||
| a) | Name | AstraZeneca PLC | ||||||
| b) | LEI | PY6ZZQWO2IZFZC3IOL08 | ||||||
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||||
| a) | Description of the financial instrument, type of instrument Identification code | AstraZeneca PLC American Depositary Shares CUSIP: 046353108 | ||||||
| b) | Nature of the transaction | Purchase of AstraZeneca PLC American Depositary Shares | ||||||
| c) | Price(s) and volume(s) | Price(s) | Volume(s) | US$38.1783 | 2,372 | US$38.175 | 100 | |
| d) | Aggregated information - Aggregated volume - Price | 2,472US$38.178 | ||||||
| e) | Date of the transaction | 29 April 2019 | ||||||
| f) | Place of the transaction | NYSE | ||||||
| 1 | Details of the person discharging managerial responsibilities / person closely associated | |||||
| a) | Name | Deborah DiSanzo | ||||
| 2 | Reason for the notification | |||||
| a) | Position/status | Non-Executive Director | ||||
| b) | Initial notification /Amendment | Initial notification | ||||
| 3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||
| a) | Name | AstraZeneca PLC | ||||
| b) | LEI | PY6ZZQWO2IZFZC3IOL08 | ||||
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||
| a) | Description of the financial instrument, type of instrument Identification code | AstraZeneca PLC American Depositary Shares CUSIP: 046353108 | ||||
| b) | Nature of the transaction | Purchase of AstraZeneca PLC American Depositary Shares | ||||
| c) | Price(s) and volume(s) | Price(s) | Volume(s) | US$38.3056 | 1,000 | |
| d) | Aggregated information - Aggregated volume - Price | Not applicable - single transaction | ||||
| e) | Date of the transaction | 29 April 2019 | ||||
| f) | Place of the transaction | NYSE | ||||
About AstraZeneca
AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in its main therapy areas - Oncology, CVRM and Respiratory. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information, please visit astrazeneca.com and follow us on Twitter @AstraZeneca.
| Media Relations | ||
| Gonzalo Viña | UK/Global | +44 203 749 5916 |
| Rob Skelding | UK/Global | +44 203 749 5821 |
| Matt Kent | UK/Global | +44 203 749 5906 |
| Jennifer Hursit | UK/Global | +44 203 749 5762 |
| Christina M Hägerstrand | Sweden | +46 8 552 53 106 |
| Michele Meixell | US | +1 302 885 2677 |
| Investor Relations | ||
| Thomas Kudsk Larsen | +44 203 749 5712 | |
| Henry Wheeler | Oncology | +44 203 749 5797 |
| Christer Gruvris | BioPharma - Cardiovascular; Metabolism | +44 203 749 5711 |
| Nick Stone | BioPharma - Respiratory; Renal | +44 203 749 5716 |
| Josie Afolabi | Other | +44 203 749 5631 |
| Craig Marks | Finance; Fixed Income | +44 7881 615 764 |
| Jennifer Kretzmann | Retail Investors; Corporate Access | +44 203 749 5824 |
| US toll-free | +1 866 381 72 77 | |
Adrian Kemp
Company Secretary
AstraZeneca PLC
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.